Viatris Inc. · NASDAQ:VTRS

Viatris — King Pharmaceuticals — Merger or Acquisition (July 2004)

18 slides from Viatris's merger presentation, Jul 26, 2004

  1. Slide 1: Acquisition of King Pharmaceuticals, Inc.

    Mylan Laboratories Inc. Acquisition of King Pharmaceuticals, Inc. Creating the Leading Diversified Specialty Pharmaceutical Company July 2004

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation will include statements that constitute "forward-looking statements", including with regard to the expected future business and financial performance of Mylan resulting from and following the acquisition and the impact of the acquisition on employees and

  3. Slide 3: Review of Transaction

    Mylan acquires King for approximately $4.0 bn in common stock Each share of King converted into 0.9 Mylan shares Total transaction value of approximately $4.2 bn, including $164 mm in net debt Attractive financial metrics 14.1x last twelve months (LTM) net income (1) 2.8x LTM revenue (1) Accretive o

  4. Slide 4: Acquisition of an Established Branded Platform

    Acquisition of an Established Branded Platform $1.5 bn diverse portfolio of branded products (1) Successful business development strategy Four major products, each exceeding $100 mm in sales (1) Altace Thrombin Strategic focus on cardiovascular with lead product, Altace ACE inhibitor $446 mm of reve

  5. Slide 5: Robust Portfolio of Acquired Products

    Robust Portfolio of Acquired Products Thrombin Skelaxin Altace Sonata Total LTM Sales: $1,474 mm Pie Label #1 566 Thrombin 148 Sonata 89 Skelaxin 225 Altace 446 Four Major Franchises Have Sales Exceeding $100 mm (1) Assuming pediatric extension, exclusivity extends to April 2009. (2) LTM revenue, in

  6. Slide 6: Profile of the Combined Company

    Profile of the Combined Company The leading generic and branded specialty pharmaceutical company Complementary strengths and expertise Powerful growth drivers Strong financial profile Robust platform to launch the next stage of our long- term growth strategies

  7. Slide 7: The Leading Generic and Branded Specialty Pharmaceutical Company

    LTM Revenues (1) (2) Global Sales Force Size (2) Mylan 200 Andrx 240 Warner Chilcott 410 Shire 767 Watson 768 Biovail 1000 Valeant 1200 King 1200 Sepracor 1250 Allergan 1300 Mylan PF 1400 Forest 2865 LTM Operating CF (1) (2) Teva 647 Mylan PF 644 Forest 628 King 418 Shire 404 Allergan 365 Biovail 24

  8. Slide 8: Combined Product Portfolio of $2.9 bn

    I. The Leading Generic and Branded Specialty Pharmaceutical Company Combined Product Portfolio of $2.9 bn (1) Generic 1096 Other Branded and Branded Generics 581 Meridian Medical 132 Altace 446 Skelaxin 258 Thrombin 148 Levoxyl 130 Sonata 116 Altace $446 Sonata(2) $116 Thrombin $148 Skelaxin(2) $258

  9. Slide 9: Complementary Strengths and Expertise

    II. Complementary Strengths and Expertise Manufacturing excellence Innovative formulation development Nebivolol opportunity Depth of legal expertise Premier customer service Strong PCP sales force Business development strength Diverse product portfolio Four key products, each with >$100 mm of sales

  10. Slide 10: Nebivolol Likely Next Large Growth Engine

    Altace Script Trends Strong Nebivolol Likely Next Large Growth Engine Next generation beta-blocker Patent until 2020 Rights in U.S. and Canada Marketed in over 45 countries excluding U.S. and Canada Highly cardio-selective that also increases nitric oxide in-vitro Well tolerated as seen in hypertens

  11. Slide 11: Powerful Growth Drivers

    "Ability to Grow" Potential 1st to File - $9 bn of Brand Sales A leading generics manufacturer Steady internal growth engine Unique science-based platform focused on difficult formulations Manufacturing excellence Approx. 10.8 bn doses shipped in fiscal 2004 Strong platform for growth R&D and legal

  12. Slide 12: Key Pro Forma Financial Metrics

    Key Pro Forma Financial Metrics (1) Strong Pro Forma Balance Sheet Will Drive Growth (3) Revenue: $2,848 mm EBITDA: $1,021 mm Operating Cash Flow: $644 mm Implied market value(2): $9.0 bn Cash: $818 mm Debt: $352 mm Debt/EBITDA: 0.3x EBITDA/ Int. Exp.: 75.8x Debt/Total Cap.: 6.0% IV. Strong Financia

  13. Slide 13: Robust Platform to Launch the Next Stage of Growth Strategies

    V. Robust Platform to Launch the Next Stage of Our Long-Term Growth Strategies Sales and marketing Manufacturing R&D Implement the optimal financial and regulatory control structure Retain and reward top talent Growth Strategies of the Business Going Forward Integrate Accelerate Growth Nebivolol lau

  14. Slide 14: Highly Experienced Senior Management Team

    We Have a Highly Experienced Senior Management Team Name Title

  15. Slide 15: Transaction Summary

    Transaction Summary Stock-for-stock exchange - tax-free transaction Implied market value of $9.0 bn (1) 0.9 Mylan shares for each King share On closing, all King shareholders become holders of Mylan shares Eligible for Mylan dividend payment Share ownership (fully-diluted) Mylan 56% King 44% Annual

  16. Slide 16: Pro Forma Financial Data

    Pro Forma Financial Data Note: Financials exclude special items. Pro forma numbers do not include any synergies or acquisition adjustments

  17. Slide 17: Conclusion

    Conclusion Creates the leading generic and branded specialty pharmaceutical company with a stable business platform and exciting growth opportunities The ideal combination of products, assets, expertise and talent Will result in a balance sheet with an investment grade profile Advances Mylan's long-

  18. Slide 18: Additional Information About the Acquisition and Where to Find It

    Additional Information About the Acquisition and Where to Find It Mylan and King will file relevant materials with the SEC, including one or more registration statement(s) that contain a prospectus and a joint proxy statement. Investors and security holders of Mylan and King are urged to carefully r

King Pharmaceuticals — Merger or Acquisition (July 2004) on 6ix